Citations

Mayo Clinic

Showing 10 of 108602 citations.

Imaging features of rare mesenychmal liver tumours: beyond haemangiomas
Thampy, Rajesh , Elsayes, Khaled M. , Menias, Christine O. , Pickhardt, Perry J. , Deshmukh, Sandeep P., Ahmed, Kareem, Korivi, Brinda Rao , Kang, HyunSeon Christine

The British Journal of Radiology | August 2, 2017 | Volume: 90 | Issue: 1079 | Pages: No page available

10.1259/bjr.20170373 | PMID 28766950 Get It

Tumours arising from mesenchymal tissue components such as vascular, fibrous and adipose tissue can manifest in the liver. Although histopathology is often necessary for definitive diagnosis, many of these lesions exhibit characteristic imaging features. The radiologist plays an important role in suggesting the diagnosis, which can direct appropriate immunohistochemical staining at histology. The aim of this review is to present clinical and imaging findings of a spectrum of mesenchymal liver tumours such as haemangioma, epithelioid haemangioendothelioma, lipoma, PEComa, angiosarcoma, inflammatory myofibroblastic tumour, solitary fibrous tumour, leiomyoma, leiomyosarcoma, Kaposi sarcoma, mesenchymal hamartoma, undifferentiated embryonal sarcoma, rhabdomyosarcoma and hepatic metastases. Knowledge of the characteristic features of these tumours will aid in guiding the radiologic diagnosis and appropriate patient management.
Transcarotid Artery Revascularization With Flow Reversal: Bypassing the Arch and Limiting Distal Emboli
Welz, Matthew E., Sattur, Mithun G. , Richter, Kent R. , Bendok, Bernard R.

Neurosurgery | August 2, 2017 | Volume: 81 | Issue: 5 | Pages: N41-N42

10.1093/neuros/nyx456 | PMID 29088470 Get It

Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes
Mahar, Alyson , Compton, Carolyn C. , Halabi, Susan , Hess, Kenneth R. , Weiser, Martin R. , Groome, Patti A. , Mahar, Alyson L , Compton, Carolyn, Halabi, Susan

Journal of Surgical Oncology | August 2, 2017 | Volume: 116 | Issue: 8 | Pages: 969-982

10.1002/jso.24774 | PMID 28767139 Get It

Integrating diverse types of prognostic information into accurate, individualized estimates of outcome in colorectal cancer is challenging. Significant heterogeneity in colorectal cancer prognostication tool quality exists. Methodology is incompletely or inadequately reported. Evaluations of the internal or external validity of the prognostic model are rarely performed. Prognostication tools are important devices for patient management, but tool reliability is compromised by poor quality. Guidance for future development of prognostication tools in colorectal cancer is needed.
The use of highly crosslinked polyethylene in total knee arthroplasty
Brown, Timothy S. , Berry, Daniel J. , Berry, Daniel J , Citters, Douglas W. Van , Abdel, Matthew P.

The Bone & Joint Journal | August 2, 2017 | Volume: 99-B | Issue: 8 | Pages: 996-1002

10.1302/0301-620x.99b8.bjj-2017-0028.r1 | PMID 28768774 Get It

Advances in polyethylene (PE) in total hip arthroplasty have led to interest and increased use of highly crosslinked PE (HXLPE) in total knee arthroplasty (TKA). Biomechanical data suggest improved wear characteristics for HXLPE inserts over conventional PE in TKA. Short-term results from registry data and few clinical trials are promising. Our aim is to present a review of the history of HXLPEs, the use of HXLPE inserts in TKA, concerns regarding potential mechanical complications, and a thorough review of the available biomechanical and clinical data.Cite this article: Bone Joint J 2017;99-B:996–1002.
Guidelines Update on Indications for Transcatheter Aortic Valve Replacement
Nishimura, Rick A., Bonow, Robert O. , O’Gara, Patrick T.

JAMA Cardiology | August 2, 2017 | Volume: 2 | Issue: 9 | Pages: 1036

10.1001/jamacardio.2017.2546 | PMID 28768333 Get It

Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis
Tomita, Kyoko, Kohli, Rohit , MacLaurin, Brittany L., Guo, Qianqian , Sanchez, Luz Helena Gutierrez , Gelbard, Harris A. , Blaxall, Burns C., Ibrahim, Samar H. , Sanchez, Luz Helena Gutierrez , Sanchez, Luz H Gutierrez, Ibrahim, Samar H , Hirsova, Petra , Guo, Qianqian , Kohli, Rohit , Gutierrez Sanchez, Luz Helena

JCI Insight | August 2, 2017 | Volume: 2 | Issue: 15 | Pages: No page available

10.1172/jci.insight.94488 | PMID 28768902 Get It

With the increase in obesity worldwide, its associated comorbidities, including nonalcoholic steatohepatitis (NASH), have become a public health problem that still lacks effective therapy. We have previously reported that mixed-lineage kinase 3–deficient (MLK3-deficient) mice are protected against diet-induced NASH. Given the critical need to identify new therapeutic agents, we sought to examine whether the small-molecule MLK3 inhibitor URMC099 would be effective in reversing diet-induced murine NASH. C57BL/6J mice were fed either a diet high in saturated fat, fructose, and cholesterol (FFC), or a chow diet for 24 weeks. Mice were treated with either URMC099 (10 mg/kg) twice daily by intraperitoneal injection or its vehicle during the last 2 weeks of the feeding study. FFC-fed mice receiving URMC099 had similar body weight, caloric intake, homeostatic model assessment of insulin resistance, metabolic phenotype, and hepatic steatosis compared with vehicle-treated mice. Furthermore, FFC-fed mice treated with URMC099 had less hepatic macrophage infiltration, activation, and proinflammatory polarization, as well as less liver injury and fibrosis when compared with vehicle-treated mice. In conclusion, URMC099 is well tolerated in mice without obvious toxicities and appears to be efficacious in reversing diet-induced NASH. Hence, URMC099 may serve as a therapeutic agent in human NASH.
Techniques and outcomes of paravalvular leak repair after transcatheter aortic valve replacement
Waterbury, Thomas M. , Reeder, Guy S., Pislaru, Sorin V. , Rihal, Charanjit S. , Eleid, Mackram F. , Cabalka, Allison K. , Eleid, Mackram F , Sabbah, Michael S. , Rihal, Charanjit S.

Catheterization and Cardiovascular Interventions | August 2, 2017 | Volume: 90 | Issue: 5 | Pages: 870-877

10.1002/ccd.27224 | PMID 28766839 Get It

AbstractObjectivesTo investigate the feasibility, procedural success, and outcomes of paravalvular leak (PVL) closure in patients with prior transcatheter aortic valve replacement (TAVR).BackgroundPVL after TAVR is associated with adverse patient outcomes and increased mortality. Percutaneous PVL closure has emerged as a therapeutic strategy for addressing this issue, but data for transcatheter PVL repair after TAVR remains limited.MethodsThis is a single center retrospective review of PVL closure after TAVR. Patients with balloon‐expandable or self‐expanding prostheses were included. Baseline patient demographics, procedural characteristics, complications, and clinical outcomes were reviewed.ResultsA total of 18 patients with clinically significant PVL after TAVR referred for PVL closure were identified during the study period. Procedural success resulting in successful transcatheter occluder plug delivery was 78% (14 cases). Balloon postdilatation (2/4) and valve‐in‐valve (2/4) were used effectively in the remaining patients after an unsuccessful PVL closure attempt. PVL grading by echocardiography decreased from moderate or severe to < moderate in 13 patients (72%). Adverse events including cardiac tamponade and acute kidney injury occurred in 1 case each. One‐month all‐cause mortality was 11%.ConclusionIn selected patients, percutaneous PVL repair following TAVR is feasible and effective for both balloon‐expandable and self‐expanding prostheses. Most patients undergoing PVL closure after TAVR require a single occluder plug placement for reduction in PVL to mild or less.
Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma
Pedrón, Sara , Hanselman, Jacob S., Harley, Brendan A.C. , Schroeder, Mark A. , Harley, Brendan A C , Sarkaria, Jann N. , Pedrón-Haba, Sara

Advanced Healthcare Materials | August 2, 2017 | Volume: 6 | Issue: 21 | Pages: No page available

10.1002/adhm.201700529 | PMID 28766870 Get It

Abstract 3D biomaterial models have potential to explore the influence of the tumor microenvironment on aberrant signaling pathways and compensatory signals using patient‐derived cells. Glioblastoma (GBM) tumors are highly heterogeneous, with both cell composition and extracellular matrix biophysical factors seen as key regulators of malignant phenotype and treatment outcomes. Amplification, overexpression, and mutation of the epidermal growth factor receptor (EGFR) tyrosine kinase have been identified in 50% of GBM patients. Here, hyaluronic acid (HA) decorated methacrylamide‐functionalized gelatin (GelMA) hydrogels are used to examine the synergies between microenvironmental factors and a model EGFR tyrosine kinase inhibitor (TKI) using patient‐derived xenograft cells. The in vitro behavior of 3 patient‐derived xenografts that reflect a clinically relevant range of EGFR variants is characterized: GBM10 (EGFR, wild type), GBM12 (EGFR+), and GBM6 (EGFRvIII). GelMA hydrogels support xenograft culture; cells remain viable, active, respond to matrix‐immobilized HA, and upregulate genes associated with matrix remodeling and tumor growth. Interestingly, matrix‐immobilized HA alters the response of GBM cells to a model tyrosine kinase inhibitor, erlotinib. While constitutively activated EGFRvIII cells are sensitive to TKI in gelatin hydrogels, hyaluronic acid mediated adhesive signaling interacts with EGFRvIII signaling to increase cell metabolic activity, increase soluble hyaluronic acid synthesis, and modify response to erlotinib exposure.
Granulocyte colony-stimulating factor significantly decreases density of hippocampal caspase 3-positive nuclei, thus ameliorating apoptosis-mediated damage, in a model of ischaemic neonatal brain injury†
Pastuszko, Peter , Schears, Gregory J. , Kubin, Joanna, Pastuszko, Anna, Wilson, David Franklin

Interactive CardioVascular and Thoracic Surgery | August 2, 2017 | Volume: 25 | Issue: 4 | Pages: 600-605

10.1093/icvts/ivx047 | PMID 28962511 Get It